Orforglipron

Orforglipron is an oral GLP‑1 agonist from Eli Lilly — a once‑daily pill with no injection — that is in Phase 3 testing for obesity and type‑2 diabetes, and community users most often try it for weight loss and appetite control, with a small number also experimenting for blood sugar management. The community modal dose is about 15 mg per day, though reported spans run from 0.5 mg to 45 mg and most users do not specify a timing schedule or cycling pattern. The off‑label evidence base is thin compared with the discussion around it, with most exploratory indications lacking posted results.

Half-life~36 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.94.01.42.83.25.0

Research Evidence

Evidence shape

The evidence base is animal‑only, confined to preclinical mechanistic research with no peer‑reviewed human studies published. Across 14 indications, two sponsors have registered 54 trials — 34 completed, 26 with posted results, a combined enrollment of 6,441 participants, 11 blinded trials reporting outcomes, and AE data aggregated from 25 trials linked to 17 publications. Nine indications remain thin or exploratory, seven are single‑trial long‑tail entries, and one is purely animal‑only, underscoring the absence of larger‑scale human evidence.

Depthhow much
53 registered trials
33 completed · 26 with posted results · 20 recruiting / active · combined n=6441
Breadthhow many areas
13 indications mapped
4 with results · 8 thin / exploratory · 1 animal-only · 6 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
11 blinded with results · AE rows aggregated from 25 trials · 16 linked publications on registered trials
Breadth and depth58 rows captured
Human
direct clinical signal
53
Animal
translational support
2
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Orforglipron side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Disguisedalpha
US
60526 mg
$149.99
$0.002/mg
2
stratelabs.is
IS
360 mg×60
$160.00
$0.44/mg
3
Happypeptides
US
270 mg×90
$165.00
$0.61/mg
4
PureHealth Peptides
US
6 mg
$129.00
$21.5/mg
5
Pure Rawz
--
6 mg
$200.98
$33.5/mg

price offers can be sorted by column

Orforglipron dosing & protocol

How Orforglipron is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 32
Typical dose
2 mg1 mg – 3 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 13 reported doses · darker = more
Frequency
daily
Route
oral

In research trials, Orforglipron was taken orally at 1–3 mg once daily, with 2 mg being the typical dose; no specific cycling regimen was reported.

32 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
10 mg
20 mg
30 mg
40 mg
50 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 82
Typical dose
15 mg500 µg – 45 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 88 reported doses · darker = more
Frequency
unspecified
Route
oral

Most community reports cite an oral dose around 15 mg, with a range from 500 µg to 45 mg, and do not specify a regular frequency or cycling pattern.

82 sources

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including FOUNDAYO. Discontinue if pancreatitis is suspected.
  • • Severe Gastrointestinal Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. FOUNDAYO is not recommended in patients with severe gastroparesis.
  • • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
  • • Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemi…
  • • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If suspected, advise the patient to promptly seek medical attention and discontinue FOUNDAYO.
  • • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression.
  • • Acute Gallbladder Disease : Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated.
  • • Pulmonary Aspiration During General Anesthesia and Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…
Contraindications
  • • FOUNDAYO is contraindicated in
  • • patients with: A personal or family history of MTC or in
  • • patients with MEN 2 [see Warnings and Precautions (5.1) ] . Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema,…
  • • patients with MEN 2 Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO
Drug interactions
  • • Inhibitors: The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 inhibitors that also inhibit OATP1B. (7.1) CYP3A4
  • • Inducers: Avoid concomitant use with strong CYP3A4 inducers. Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers. (7.1)
  • • Simvastatin: Do not exceed simvastatin 20 mg once daily when used concomitantly with FOUNDAYO. (7.2) FOUNDAYO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.3)

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604CagrilintideLiraglutideExenatideTesamorelinEloralintideMazdutideTesofensine